← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $616B	4,161	+44	+1%	$289B
2	2 AbbVie ABBV $503B	3,828	+76	+2%	$270B
3	3 Merck MRK $362B	3,457	-159	-4%	$178B
4	4 Pfizer PFE $169B	2,939	-65	-2%	$95.2B
5	5 Amgen AMGN $235B	2,935	+73	+3%	$134B
6	6 Bristol-Myers Squibb BMY $124B	2,487	-8	-0.3%	$99.5B
7	7 Gilead Sciences GILD $194B	2,019	+129	+7%	$119B
8	8 Novartis NVS $287B	1,359	+17	+1%	$15.4B
9	9 Regeneron Pharmaceuticals REGN $81.6B	1,293	-28	-2%	$59.1B
10	10 AstraZeneca AZN $257B	1,253	+32	+3%	$37.3B
11	11 GSK GSK $99.4B	860	+10	+1%	$14.2B
12	12 Incyte INCY $22.9B	630	-21	-3%	$11.5B
13	13 Natera NTRA $56.3B	599	+3	+0.5%	$18.4B
14	14 Exelixis EXEL $15.4B	559	+39	+8%	$9.38B
15	15 DELISTED Exact Sciences EXAS	558	-37	-6%	$7.89B
16	16 Jazz Pharmaceuticals JAZZ $13.6B	551	+42	+8%	$7.45B
17	17 Halozyme HALO $13.7B	550	+41	+8%	$7.74B
18	18 Lantheus LNTH $6.52B	526	+39	+8%	$7.7B
19	19 DELISTED Blueprint Medicines BPMC	353	+7	+2%	$6.12B
20	20 Guardant Health GH $21.4B	342	+44	+15%	$5.1B
21	21 Recursion Pharmaceuticals RXRX $1.96B	336	+20	+6%	$1.63B
22	22 Takeda Pharmaceutical TAK $62.7B	310	+8	+3%	$1.06B
23	23 DELISTED SpringWorks Therapeutics SWTX	306	+90	+42%	$3.29B
24	24 Iovance Biotherapeutics IOVA $6.22B	302	+1	+0.3%	$799M
25	25 Qiagen QGEN $9.54B	300	-26	-8%	$5.92B